阿达木单抗治疗白塞病相关葡萄膜炎的累积留存率:四年随访研究
该研究纳入2009年1月至2016年12月间接受阿达木单抗(ADA)治疗的白塞病(BD)相关葡萄膜炎患者54例(82眼),随访48个月,12个月和48个月药物留存率分别为76.9%和63.5%,合并使用改善病情抗风湿药(DMARDs)及不同生物制剂治疗线数均不影响留存率,BD葡萄膜炎的不良预后因素不影响ADA疗效。
要点
- ADA治疗BD相关葡萄膜炎48个月留存率为63.5%,12个月为76.9%。
- 合并使用DMARDs与否及不同生物制剂治疗线数间留存率无显著差异。
- 年龄、BD发病年龄、葡萄膜炎发病年龄、BD病程、葡萄膜炎病程、HLA-B51阳性及性别在继续与停用ADA患者间无显著差异。
核心结论
- ADA在BD相关葡萄膜炎中的留存率良好,且不受合并使用DMARDs或不同生物制剂治疗线数影响。
- BD葡萄膜炎的负面预后因素不影响ADA疗效。
研究设计与样本
- 研究纳入2009年1月至2016年12月间诊断为BD相关葡萄膜炎并接受ADA治疗的患者。
- 采用Kaplan-Meier法研究累积生存率,用log-rank(Mantel-Cox)检验比较生存曲线。
- 共54例连续患者(82眼)符合分析条件。
主要发现
- 12个月和48个月随访时药物留存率分别为76.9%和63.5%。
- 合并使用DMARDs与否组间无统计学显著差异(p=0.27)。
- 不同ADA治疗线数组间无统计学显著差异(p=0.37)。
- 继续与停用ADA患者在年龄(p=0.24)、BD发病年龄(p=0.81)、葡萄膜炎发病年龄(p=0.56)、总体BD病程(p=0.055)、葡萄膜炎病程(p=0.46)、HLA-B51阳性(p=0.51)及性别(p=0.47)方面均无显著差异。
关键数值与推荐
- 12个月药物留存率为76.9%,48个月为63.5%。
- 合并使用DMARDs比较p=0.27,不同生物制剂治疗线数比较p=0.37。
- 年龄p=0.24,BD发病年龄p=0.81,葡萄膜炎发病年龄p=0.56,总体BD病程p=0.055,葡萄膜炎病程p=0.46,HLA-B51阳性p=0.51,性别p=0.47。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated. METHODS: We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA. RESULTS: 54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47). CONCLUSIONS: ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy.
引用
- Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2017. PMID: 28844047. doi:10.1136/bjophthalmol-2017-310733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。